Alzheimers Disease Drug Development: Old Problems Require New Priorities

Drug misuse in older people: old problems and new challenges

Very little attention has been paid to the invisible epidemic of substance misuse among older people in the UK. This article looks at the prevalence of substance misuse in the people over the age of 60. The reasons for difficulty in diagnosing substance misuse are explored and ways to improve diagnostic ability are discussed. Substance misuse leads to severe physical and psychiatric morbidity t...

Parkinson's disease--challenges in new drug development.

Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disorder after Alzheimer's disease. Treatment aims in IPD include the provision of symptomatic relief reduction of functional disability, halting or slowing of the neurodegenerative process, and the prevention of long-term complications by proper initiation of therapy. At present, pharmacotherapeutic strategies all...

New Challenges and Old Problems

Oxytocin: Old Hormone, New Drug

Oxytocin (OT), traditionally associated with reproductive functions, was revisited recently, and several new functions in cardiovascular regulation were discovered. These functions include stimulation of the cardioprotective mediators nitric oxide (NO) and atrial natriuretic peptide. OT's cardiovascular outcomes comprise: (i) natriuresis, (ii) blood pressure reduction, (iii) negative inotropic ...

New Insights to Old Problems

From the history of the θ-τ puzzle and the discovery of parity non-conservation in 1956, we review the current status of discrete symmetry violations in the weak interaction. Possible origin of these symmetry violations are discussed. PACS: 11.30.Er, 12.15.Ff, 14.60.Pq